Physician profile
Kyle Edwin Zoll
NPI 1851822423
$2,192.52
in general payments reported to CMS, 2019-2025
23 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $152 · 2023: $614 · 2024: $869 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $38.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.14 |
| Education | $38.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $366.19 | 2022-2025 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $332.74 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $261.44 | 2022-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $193.15 | 2023-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $121.64 | 2022-2024 | |
| Travere Therapeutics, INC. | $119.83 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.02 | 2022-2024 | Farxiga |
| Novo Nordisk INC | $108.28 | 2023-2025 | Rivfloza, Ozempic, Wegovy |
| Calliditas Therapeutics US INC. | $96.47 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $90.15 | 2023-2025 | Benlysta |
| Horizon Therapeutics Plc | $73.04 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $62.27 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $43.60 | 2023 | |
| Aurinia Pharma U.S., INC. | $35.20 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $34.68 | 2023 | Veltassa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $21.79 | 2023 | Rayaldee |
| Akebia Therapeutics INC | $20.86 | 2024 | Auryxia, Vafseo |
| Kyowa Kirin, INC. | $19.79 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.67 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $17.35 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.40 | 2023 | Keveyis |
| Lilly USA, LLC | $15.11 | 2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $13.85 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Zoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.